UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study

Breast (Edinburgh), 2024-04, Vol.74, p.103681-103681, Article 103681

2024

Link zum Volltext

Verfügbarkeit prüfen

Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial

Radiology and oncology, 2022-05, Vol.56 (2), p.238-247

2022

Link zum Volltext

Verfügbarkeit prüfen

MiR-34b is associated with clinical outcome in triple-negative breast cancer patients

Diagnostic pathology, 2012-03, Vol.7 (1), p.31-31, Article 31

2012

Link zum Volltext

Verfügbarkeit prüfen

Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial

Breast cancer research and treatment, 2022-05, Vol.193 (1), p.95-103

2022

Link zum Volltext

Verfügbarkeit prüfen

The impact of the 21-gene assay in the Czech Republic on adjuvant chemotherapy (CT) recommendations and costs in estrogen receptor positive (ER+) early stage breast cancer (ESBC) patients with grade 2 tumors and risk factors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e12061-e12061

2016

Link zum Volltext

Verfügbarkeit prüfen

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1002-1002

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-181: The impact of Ras/MAPK/S6K signaling pathway on prediction of clinical outcome in metastatic Her-2 positive breast cancer patients treated with trastuzumab

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.LB-181-LB-181

2014

Link zum Volltext

Verfügbarkeit prüfen

Genetic and preventive services for hereditary breast and ovarian cancer in the czech republic

Hereditary cancer in clinical practice, 2006-11, Vol.4 (1), p.3-6, Article 3

2006

Link zum Volltext

Verfügbarkeit prüfen

Long-term control of brain metastases in breast cancer patients by lapatinib

Breast (Edinburgh), 2011-10, Vol.20, p.S37-S37

2011

Link zum Volltext

Verfügbarkeit prüfen

Systemic treatment of breast cancer in young patients with a germline mutation in the BRCA1 and BRCA2 genes

Onkologie (Olomouc), 2023-06, Vol.17 (3), p.145-149

Palácová, Markéta

2023

Link zum Volltext

Verfügbarkeit prüfen

Sacituzumab govitecan in the treatment of metastatic triple negative breast cancer

Onkologie (Olomouc), 2023-06, Vol.17 (3), p.160-163

Palácová, Markéta

2023

Link zum Volltext

Verfügbarkeit prüfen

Breast Cancer in BRCA1/2 Mutation Carriers - Do We Treat It Differently? Focus on Systemic Therapy for BRCA1/2 Associated Breast Cancer

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2019, Vol.32 (Supplementum2), p.24

Palácová, Markéta

2019

Link zum Volltext

Verfügbarkeit prüfen

Hormonal therapy in premenopausal patients with SR-positive, HER2-negative breast cancer

Onkologie (Olomouc), 2019-03, Vol.13 (1), p.24-28

Palácová, Markéta

2019

Link zum Volltext

Verfügbarkeit prüfen

Ovarian Ablation in Breast Cancer Patients and the Possibility of Influencing Treatment Side Effects

Klinická onkologie, 2016, Vol.29 Suppl 3 (Suppl 3), p.S29-3S38

Palácová, M

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract PS14-03: Ribociclib + letrozole in male patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS14-03-PS14-03

2021

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2019-08, Vol.32 (Supplementum2), p.6

2019

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer

Klinická onkologie, 2019-08, Vol.32 (Suppl 2)

2019

Link zum Volltext

Verfügbarkeit prüfen

Hereditary Breast and Ovarian Cancer Syndrome

Klinická onkologie, 2016-01, Vol.29 Suppl 1 (Suppl 1), p.S14-S21

2016

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2019, Vol.32 (Supplementum2), p.31

2019

Link zum Volltext

Verfügbarkeit prüfen

Triple Negative Breast Cancer

Klinická onkologie, 2015-12, Vol.28 (6), p.406-415

2015

Link zum Volltext

Verfügbarkeit prüfen

Circulating Levels of Estradiol in Breast Cancer Patients Treated with Aromatase Inhibitors and Their Clinical Implications

Klinická onkologie, 2016, Vol.29 Suppl 3 (Suppl 3), p.S50-3S57

2016

Link zum Volltext

Verfügbarkeit prüfen

Recommended Extension of Indication Criteria for Genetic Testing of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Syndrome

Klinická onkologie, 2016, Vol.29 Suppl 1 (Suppl 1), p.S9-S13

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(26)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(15)
Female
(14)
Breast Neoplasms - Drug Therapy
(7)
Adult
(6)
Breast Cancer
(6)
Breast Neoplasms - Pathology
(6)
Life Sciences & Biomedicine
(6)
Middle Aged
(6)
Science & Technology
(6)
Aged
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Breast Neoplasms - Genetics
(5)
Chemotherapy
(4)
Male
(4)
Mutation
(4)
Oncology
(4)
Patients
(4)
Treatment Outcome
(4)
Analysis
(3)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study

Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial

MiR-34b is associated with clinical outcome in triple-negative breast cancer patients

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial

The impact of the 21-gene assay in the Czech Republic on adjuvant chemotherapy (CT) recommendations and costs in estrogen receptor positive (ER+) early stage breast cancer (ESBC) patients with grade 2 tumors and risk factors

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial

Abstract LB-181: The impact of Ras/MAPK/S6K signaling pathway on prediction of clinical outcome in metastatic Her-2 positive breast cancer patients treated with trastuzumab

Genetic and preventive services for hereditary breast and ovarian cancer in the czech republic

Long-term control of brain metastases in breast cancer patients by lapatinib

Systemic treatment of breast cancer in young patients with a germline mutation in the BRCA1 and BRCA2 genes

Sacituzumab govitecan in the treatment of metastatic triple negative breast cancer

Breast Cancer in BRCA1/2 Mutation Carriers - Do We Treat It Differently? Focus on Systemic Therapy for BRCA1/2 Associated Breast Cancer

Hormonal therapy in premenopausal patients with SR-positive, HER2-negative breast cancer

Ovarian Ablation in Breast Cancer Patients and the Possibility of Influencing Treatment Side Effects

Abstract PS14-03: Ribociclib + letrozole in male patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial

Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer

Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer

Hereditary Breast and Ovarian Cancer Syndrome

Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno

Triple Negative Breast Cancer

Circulating Levels of Estradiol in Breast Cancer Patients Treated with Aromatase Inhibitors and Their Clinical Implications

Recommended Extension of Indication Criteria for Genetic Testing of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Syndrome

Suchergebnisse filtern